Envista (NYSE:NVST) this week posted second-quarter results that beat the earnings consensus on Wall Street but missed revenue estimates. The Brea, California-based dental technology company reported profits of $47.1 million, or 26¢ per share, on sales of $645.8 million for the three months ended July 1, for a bottom-line loss of 47.7% on sales growth […]
Envista
Envista rises on Street-beating Q1 results
Envista (NYSE:NVST) shares are on the rise on first-quarter results that came in ahead of the consensus forecast. The Brea, California-based dental technology company posted profits of $74.9 million, or 42¢ per share, on sales of $631.4 million for the three months ended April 1, 2022, for a 4.5% bottom-line gain on sales growth of […]
Envista posts Street-beating Q4
Envista (NYSE:NVST) shares ticked up before hours today on fourth-quarter results that topped the consensus forecast. The Brea, California-based dental technology company posted profits of $85.8 million, or 48¢ per share, on sales of $651.8 million for the three months ended Dec. 31, 2021, for a 20.8% bottom-line slide on sales growth of 5.8%. Adjusted […]
FDA clears Nobel Biocare’s N1 implant system
Envista (NYSE:NVST) announced today that the FDA cleared the Nobel Biocare N1 implant system of instruments, prosthetic components and surgical protocols. The N1 system includes an implant designed for immediate placement and predictable insertion torques, providing a trioval conical connection for the abutment to slide into place. Additionally, the system has an emergence profile designed […]
Envista selling its KaVo unit to Planmeca for up to $455M
Envista this week announced that it has entered into a binding agreement to sell its KaVo treatment unit and instrument business to Planmeca for up to $455 million. Through the deal, Planmeca will pay up to $455 million with a potential earn-out payment of up to $30 million. The sale is expected to close at […]
Envista posts Street-beating Q2 results
Envista (NYSE:NVST) today posted second-quarter results that beat the overall consensus on Wall Street. The Brea, Calif.-based company reported profits of $90.1 million, or 51¢ per share, on sales of $740.1 million for the three months ended July 2, for a sales growth of 104.45% compared with Q2 2020. Adjusted to exclude one-time items, earnings per […]
Danaher completes spinoff of dental business into Envista
Danaher (NYSE:DHR) today announced the completion of split-off exchange offer of all the shares of the common stock belonging to its dental business spinout Envista (NYSE:NVST). The Envista common stock held by Danaher is slated to be exchanged for shares of Danaher’s common stock. Danaher accepted an aggregate of more than 22.9 million shares of Danaher common […]
Danaher lists offering of Envista stock
Danaher (NYSE:DHR) initiated an offer to exchange nearly 130 million shares of common stock of its dental business spinout Envista (NYSE:NVST). In the exchange of up to an aggregate of 127,868,000 shares of Envista stock, which is listed at $27.70 per share in midday trading today, for each $100 of Danaher common stock accepted, approximately $107.53 of […]
Danaher dental spinout Envista closes $677m IPO
Envista (NYSE:NVST), the dental business spinout from Danaher (NYSE:DHR), last week closed its initial public offering at $677 million, including more than $88 million from the underwriters. Brea, Calif.-based Envista floated nearly 26.8 million shares at $22.00 apiece, grossing $588.9 million, plus more than 4.0 million shares in fully subscribed underwriters option. Net proceeds of about $643.4 million […]
Danaher dental spinout Envista prices $589m IPO
Envista (NYSE:NVST), the dental business spinout from Danaher (NYSE:DHR), yesterday priced its initial public offering at $589 million, sending its overall valuation well above the $3 billion mark. The spinout, announced in July 2018, will unite the Nobel Biocare, KaVo Kerr and Ormco dental brands under the Envista umbrella. The nearly 26.8-million-share flotation, at $22 per share, is for […]
Danaher dental spinout Envista preps $600m IPO
The dental business spinout at Danaher (NYSE:DHR), Envista, is gearing up for a $600 million initial public offering this week. The spinout, announced in July 2018, will unite the Nobel Biocare, KaVo Kerr and Ormco dental brands under the Envista umbrella. The newly public company, which employs some 12,000 workers, is headquartered in Brea, Calif. Envista […]